Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

NCT07007728 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
Secondary Malignant Neoplasm of Liver

Interventions

DRUG: Iparomlimab/Tuvonralimab
DRUG: Bevacizumab + CAPEOX
PROCEDURE: Surgical resection ± ablation or stereotactic radiotherapy (if applicable)

Sponsor

Peking University Cancer Hospital & Institute